FDA Issued 30 Warning Letters to Telehealth Companies — Here's Who Got Caught
The FDA named names. STAT found that 30% of warned companies share clinical DNA through just four medical groups. Here's what the letters actually said, who received them, and how to verify your own provider.
What the FDA did
On March 3, 2026, the FDA announced 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products. This was the second wave — following over 100 letters sent in 2025. FDA Commissioner Marty Makary called it "a new era" of enforcement, noting that the volume of warning letters in the preceding six months exceeded the total of the entire previous decade.
Then on February 6, 2026, the Department of Health and Human Services referred Hims & Hers Health to the Department of Justice for investigation related to compounded drug marketing. This is the highest-profile enforcement action in the telehealth industry to date.
Companies specifically named in FDA warnings include: Lovely Meds, Hello Cake, MEDVi, Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, and GoodGirlRx. STAT News found that at least 30% of warned companies share clinical infrastructure through just four medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra.
The three violations that triggered letters
The FDA's letters focused on three categories of misconduct:
1. "Sameness" claims. Marketing materials implied that compounded GLP-1s were identical to FDA-approved drugs like Wegovy or Ozempic. They are not. Compounded medications are not evaluated by the FDA for safety, efficacy, or quality.
2. Obscured sourcing. Companies branded products with their own name — as if they manufactured the medication — without disclosing that a separate compounding pharmacy actually prepared it. This masks the real source and makes accountability harder.
3. Implied FDA approval. Promotional materials used language that suggested FDA had reviewed or approved the compounded products. The FDA has never approved any compounded GLP-1.
How to verify your provider
✅ Five-point compliance check:
1. The provider names the compounding pharmacy (name + license number)
2. The site states clearly that compounded drugs are NOT FDA-approved
3. A licensed prescriber reviews your health history before dispensing
4. The product label shows the pharmacy's name — not just the telehealth brand
5. Marketing does not use brand names (Ozempic, Wegovy, Mounjaro) as if the product is the same
The providers below have passed our compliance review as of April 2026. Sesame Care sidesteps the compounding question entirely by prescribing only FDA-approved brand-name medications. The compounded providers listed disclose their pharmacy partnerships and carry appropriate disclaimers.
Paid links · Providers we track
Providers That Passed Our Compliance Review
| Provider | Category | Starting | |
|---|---|---|---|
| Sesame Care | GLP-1 (brand) | from $199 | View Provider → |
| Embody | GLP-1 | $400 CPA | View Provider → |
| Yucca Health | GLP-1 | from $149/mo | View Provider → |
| Care Bare Rx | GLP-1 | from $169/mo | View Provider → |
| Eden Health | GLP-1 | from $199/mo | View Provider → |
Compounded medications are not FDA-approved. Verify pricing on provider's site before enrolling.
What this means for patients
If you're currently using a compounded GLP-1 from a telehealth provider, don't panic — but do verify. The FDA is targeting bad marketing, not compounding itself. Legitimate compounding under 503A/503B pathways remains legal. But if your provider was on the warning list, or if they can't answer the five questions above, it's time to switch.
How we evaluate: Virtual Health Visits reviews providers based on licensing, pricing transparency, clinical quality, and patient experience. We earn commissions from some providers, which does not influence our coverage. Full methodology →
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. Consult a licensed clinician before starting any treatment.